A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease

Fiocchi, Jacob; Urits, Ivan; Orhurhu, Vwaire; Orhurhu, Mariam Salisu; Giacomazzi, Stephen; Hoyt, Briggs; Kaye, Alan D.; Viswanath, Omar

doi:10.1007/s11916-020-00854-y

Cited by 11 publications

(2 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Existing evidence shows that treating concurrent psychological problems appropriately enhances patient quality of life. To further understand techniques of chronic pain management in sickle cell disease, more large randomized controlled research are needed [18]. Acute and chronic pain are the most common complication of sickle cell disease however being a prevalent issue literature is lacking regarding the clinical studies more research in future is needed to study the effects of various management strategies for pain to develop more efficient guidelines and recommendations regarding pain management in sickle cell disease.…”

Section: Fig 1 Management Of Pain In Sickle Cell Disease Patientsmentioning

confidence: 99%

Acute and Chronic Pain Management in Sickle Cell Disease

Alsomali

Harshan²,

Alnakhlie³

et al. 2022

JPRI

View full text Add to dashboard Cite

Sickle cell disease is a genetic haemoglobin disorder affecting millions of people worldwide. Pain is one of the most commonly reported complication of sickle cell disease. Pain is further classified into two categories acute pain and chronic pain. Chronic pain is associated with more serious complications. Management of pain has a significant impact on quality of life of sickle cell disease patients. The purpose of this research is to review the available information about acute and chronic pain management in sickle cell disease. The best treatment for both acute and chronic pain requires a customized, varied approach. This approach combines therapeutic, non-pharmacological therapies, as well as integrated therapies as per the specific needs of each patient. Opioids are effectively used in management of the pain of sickle cell disease and their use is supported by literature especially in chronic pain. Methadone, ketamine, and nitrous oxide are also used to manage pain. For the treatment of acute pain, nonsteroidal anti-inflammatory medications, short-acting opioids, and adjuvants are used effectively in clinical practice. Opioids have become the recommended treatment for pain in sickle cell disease, and many chronic pain patients are sustained on opioid therapy for the rest of their lives. However, the distinction between acute and chronic opioid therapy modalities is blurred in sickle cell disease due to the association between recurring acute pain and chronic pain. Limited literature is available regarding management guidelines and therapeutic strategies so more clinical research and trials are needed in future to design and study effective management strategies for both acute and chronic pain.

show abstract

Section: Fig 1 Management Of Pain In Sickle Cell Disease Patientsmentioning

confidence: 99%

Acute and Chronic Pain Management in Sickle Cell Disease

Alsomali

Harshan²,

Alnakhlie³

et al. 2022

JPRI

View full text Add to dashboard Cite

show abstract

“…It is a significant burden especially in Africa, with increased child morbidity and mortality (Oron et al, 2020). It is the most common reason for hospitalization of children with SCD and contributes to the high cost of medical care (Fiocchi et al, 2020). Socio-demographic characteristics, such as age, gender, and socioeconomic status, have been studied in relation to musculoskeletal pain in children with sickle cell disease (SCD) in developed and developing countries.…”

Section: Introductionmentioning

confidence: 99%

Exploring the Association of Sociodemographic Factors with Musculoskeletal Pain among Children with Sickle Cell Disease

R.,

J.,

2023

African Journal of Health, Nursing and Midwifery

View full text Add to dashboard Cite

Musculoskeletal pain is the most common manifestation among children with Sickle Cell Disease. Objective: This study aimed at evaluating the relationship between sociodemographic characteristics and musculoskeletal pain among children with sickle cell disease. Methodology: This was a cross-sectional analytical design. Results: Majority of participants were 9 years and above (55.1%) and females (55.7%). Most participants belonged to the upper class (64.8%), identified as Christians (80.7%), and resided in rural areas (75.6%). Descriptive analysis revealed that musculoskeletal pain was present in both mild and moderate forms. Inferential analysis showed no significant associations between sociodemographic characteristics (age groups, gender, class, religion, residence, parental marital status, parental socioeconomic status, number of family members and musculoskeletal pain severity among children with sickle cell disease (p > 0.05). Conclusion: Sociodemographic characteristics may not significantly influence musculoskeletal pain severity among children with sickle cell disease.

show abstract

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Ala,

Joshi,

Gupta

et al. 2024

Archiv der Pharmazie

View full text Add to dashboard Cite

Sickle cell disease (SCD) is an autosomal recessive genetic disorder that occurs due to the point mutation in the β‐globin gene, which results in the formation of sickle hemoglobin (HbS) in the red blood cells (RBCs). When HbS is exposed to an oxygen‐depleted environment, it polymerizes, resulting in hemolysis, vaso‐occlusion pain, and impaired blood flow. Still, there is no affordable cure for this inherited disease. Approved medications held promise but were met with challenges due to limited patient tolerance and undesired side effects, thereby inhibiting their ability to enhance the quality of life across various individuals with SCD. Progress has been made in understanding the pathophysiology of SCD during the past few decades, leading to the discovery of novel targets and therapies. However, there is a compelling need for research to discover medications with improved efficacy and reduced side effects. Also, more clinical investigations on various drug combinations with different mechanisms of action are needed. This review comprehensively presents therapeutic approaches for SCD, including those currently available or under investigation. It covers fundamental aspects of the disease, such as epidemiology and pathophysiology, and provides detailed discussions on various disease‐modifying agents. Additionally, expert insights are offered on the future development of pharmacotherapy for SCD.

show abstract

A Comprehensive Review of the Treatment and Management of Pain in Sickle Cell Disease

Cited by 11 publications

References 76 publications

Acute and Chronic Pain Management in Sickle Cell Disease

Acute and Chronic Pain Management in Sickle Cell Disease

Exploring the Association of Sociodemographic Factors with Musculoskeletal Pain among Children with Sickle Cell Disease

A critical review of therapeutic interventions in sickle cell disease: Progress and challenges

Contact Info

Product

Resources

About